3-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethoxy)propanoic acid

Catalog No. :
ACPQBG251
CAS No. :
2682112-08-7
Molecular Formula :
C20H22N2O9
Molecular Weight :
434.40

IUPAC Name:3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethoxy)propanoic acid

3-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethoxy)propanoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25mg98%$585.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethoxy)propanoic acid
IUPAC Name3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethoxy)propanoic acid
Molecular FormulaC20H22N2O9
Molecular Weight434.40
SMILESO=C(O)CCOCCOCCOC1=CC2=C(C(N(C(CC3)C(NC3=O)=O)C2=O)=O)C=C1
InChI KeyPZDWKEFNXUZNPV-UHFFFAOYSA-N
SynonymPropanoic acid, 3-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]oxy]ethoxy]ethoxy]-;3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethoxy)propanoic acid;Thalidomide-5-PEG3-COOH
CAS No.2682112-08-7

Safety Data

Pictogram
Health hazardToxic
Signal Word
Danger
Hazard Statement(s)
H301-H312-H360
Precautionary Statement(s)
P201-P202-P264-P270-P280-P301+P310+P330-P302+P352+P312-P308+P313-P405-P501

Synthetic Route by SureRoute

1. ACPQBG251 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPQBG251 route product structure diagram
    ACPQBG2512682112-08-7
Inquiry

2. ACPQBG251 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPQBG251 route product structure diagram
    ACPQBG2512682112-08-7
Inquiry

Comments (0)